Effect of iron containing phosphate binder on iron metabolism of patients undergoing maintenance hemodialysis.

Not Applicable

• Conditions: Chronic kidney disease

• Registration Number: JPRN-UMIN000023700
• Lead Sponsor: Hyogo College of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-10-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients who received maintenance hemodialysis for < 6month. 2) Patients with severe heart failure (>NYHA III), respiratory failure, malignancy disease, or severe liver dysfunction. 3) Patient with high serum ferritin level(>100 ng/mL) at the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adverse events (cerebral cardiovascular disease, infection, hospitalization) and survival.

Secondary Outcome Measures

Name	Time	Method
The effect of iron containing phosphate binder on the anemia (Hb, Ret, RDW,dose of iron and ESA), iron metabolism(ferritin, TSAT, hepcidin, NTBI), CKD-MBD(Ca, P, FGF23,dose of phosphate binder, vitaminD, cinacalcet), arteriosclerosis (PWV, ABI, TMAO, LVMI), and microbiome.